P51449 (RORG_HUMAN) Homo sapiens (Human)
Nuclear receptor ROR-gamma UniProtKBInterProSTRINGInteractive Modelling
Available Structures
157 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Crystal structure of orphan nuclear receptor RORgamma in complex with natural ligand |
Heteromer Q15596; | 100 | 1×HC3; | |||
| ROR gamma in complex with SCR2 and compound 3 |
Heteromer Q15596; | 100 | 2×WB7; 1×GOL; | |||
| Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for … |
Heteromer P48552; | 99.59 | 1×98N; | |||
| RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST "CPD-9" AND RIP140 PEPTIDE AT 1.66A |
Heteromer P48552; | 99.59 | 1×EEZ; | |||
| RORGT (264-518;C455S) IN COMPLEX WITH THE FRAGMENT ("CPD-1") AND RIP140 PEPTIDE AT 1.80A |
Heteromer P48552; | 99.59 | 1×EE8; | |||
| Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for … |
Heteromer P48552; | 99.59 | 1×8YB; | |||
| RORGT (264-518;C455S) IN COMPLEX WITH INVERSE AGONIST "CPD-2" AND RIP140 PEPTIDE AT 1.90A |
Heteromer P48552; | 99.59 | 1×EF5; | |||
| Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for … |
Heteromer P48552; | 99.59 | 1×98H; | |||
| Crystal structure of the orphan nuclear receptor ROR(gamma)t ligand-binding domain in complex with … |
Heteromer Q15596; | 100 | 1×NBH; 1×DMX; | |||
| Structure of RORgt in complex with a novel agonist. |
Heteromer Q15788; | 100 | 1×EDO; 1×HOJ; | |||
| Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for … |
Heteromer P48552; | 99.59 | 1×C3S; | |||
| Crystal structure of the orphan nuclear receptor RORgamma ligand-binding domain in complex with 4al… |
Heteromer P48552; | 100 | 6×4D8; | |||
| Ligand complex of RORg LBD |
Heteromer Q15596; | 100 | 1×VYI; 1×DMS; | |||
| Ligand complex of RORg LBD |
Heteromer Q15596; | 100 | 1×JUH; 1×NA; 1×DMS; | |||
| Ligand complex of RORg LBD |
Heteromer Q15596; | 100 | 1×VCH; 2×DMS; 1×NA; | |||
| Ligand complex of RORg LBD |
Heteromer Q15596; | 100 | 1×4TU; 1×NA; | |||
| Ligand complex of RORg LBD |
Heteromer Q15596; | 100 | 1×6VD; 1×NA; | |||
| Crystal structure of RORgamma in complex with natural inverse agonist |
Heteromer Q15596; | 100 | 1×88K; | |||
| Ligand complex of RORg LBD |
Heteromer Q15596; | 100 | 1×8Y5; 1×NA; 1×DMS; | |||
| Ligand complex of RORg LBD |
Heteromer Q15596; | 100 | 1×I6G; 1×SWX; 1×YTZ; 1×NA; 1×DMS; | |||
| Ligand complex of RORg LBD |
Heteromer Q15596; | 100 | 1×BWE; 1×NA; | |||
| Ligand complex of RORg LBD |
Heteromer Q15596; | 100 | 1×JUN; 1×DMS; 1×NA; | |||
| Ligand complex of RORg LBD |
Heteromer Q15596; | 100 | 1×8Y2; 1×NA; | |||
| Ligand complex of RORg LBD |
Heteromer Q15596; | 100 | 1×VCK; 1×NA; 1×DMS; | |||
| Crystal structure of RORgamma in complex with natural inverse agonist |
Heteromer Q15596; | 100.0 | 1×97I; | |||
| Ligand complex of RORg LBD |
Heteromer Q15596; | 100 | 1×A7W; 1×NA; 1×DMS; | |||
| Ligand complex of RORg LBD |
Heteromer Q15596; | 100 | 1×76E; 1×NA; | |||
| Ligand complex of RORg LBD |
Heteromer Q15596; | 100 | 1×JUE; 1×NA; | |||
| RORgamma (263-509) complexed with SRC2 and Compound 6 |
Heteromer Q15788; | 100 | 1×4CX; | |||
| Ligand complex of RORg LBD |
Heteromer Q15596; | 100 | 1×8YB; 1×NA; | |||
| Crystal structure of orphan nuclear receptor RORgamma in complex with natural ligand |
Heteromer Q15596; | 100 | 1×HC2; | |||
| Crystal structure of orphan nuclear receptor RORgamma in complex with natural ligand |
Heteromer Q15596; | 100 | 1×HC9; | |||
| Ligand complex of RORg LBD |
Heteromer Q15596; | 100 | 1×8Y8; 1×NA; 1×DMS; | |||
| Ligand complex of RORg LBD |
Heteromer Q15596; | 100 | 1×5IM; | |||
| Crystal structure of RORgamma complexed with SRC2 and compound 5d |
Heteromer Q15596; | 100 | 1×4CZ; | |||
| Ligand complex of RORg LBD |
Heteromer | 100 | 2×76E; | |||
| Complex of a Gemini-cholesterol analogue with Retinoid-related Orphan Receptor gamma |
Heteromer | 100 | 4×ACT; 2×ECK; | |||
| Ternary complex of Human ROR gamma Ligand Binding Domain With Compound T. |
Heteromer Q9Y618; | 99.13 | 1×9P6; | |||
| Crystal Structure of the mutant Human ROR gamma Ligand Binding Domain With rockogenin. |
Heteromer Q9Y618; | 99.12 | 1×82R; | |||
| Crystal Structure of the mutant Human ROR gamma Ligand Binding Domain With JTE-151 |
Heteromer Q9Y618; | 99.12 | 1×YAL; | |||
| Discovery of the Second Generation ROR gamma Inhibitors Composed of an Azole Scaffold. |
Heteromer Q9Y618; | 99.12 | 1×AYO; | |||
| Crystal structure of RORc in complex with a partial inverse agonist compound | homo-2-mer | 100 | 2×3QQ; 2×TLA; | |||
| Structure of RORgt bound to a tertiary alcohol | homo-2-mer | 100 | 2×9WD; | |||
| Structure of RORgt bound to a tertiary alcohol | homo-2-mer | 99.52 | 2×9WA; | |||
| Crystal Structure of human RORgamma (C455E) LBD in complex with compound XY039 | homo-2-mer | 99.5 | 2×H4I; 4×GOL; 2×EOH; | |||
| HUMAN RETENOID-RELATED ORPHAN RECEPTOR-GAMMA (RORC2) LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND… | monomer | 99.2 | 1×XO5; 1×XNX; | |||
| HUMAN RETENOID-RELATED ORPHAN RECEPTOR-GAMMA (RORC2) LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND… | monomer | 99.19 | 1×LKY; 1×4Y5; 1×SO4; | |||
| HUMAN RETENOID-RELATED ORPHAN RECEPTOR-GAMMA (RORC2) LIGAND-BINDING DOMAIN IN COMPLEX WITH COMPOUND… | monomer | 99.19 | 1×XNR; 2×4Y5; | |||
| Crystal structure of RORc in complex with a phenyl sulfonamide agonist | monomer | 100 | 1×3SN; | |||
| RORgammat LBD complexed with Ursonic Acid and SRC2.2 | monomer | 100 | 1×B8F; | |||
| RORy in complex with T090131718 and Coactivator peptide EBI96 | monomer | 100 | 1×444; | |||
| SUBSTITUTED BENZYLOXYTRICYCLIC COMPOUNDS AS RETINOIC ACID-RELATED ORPHAN RECEPTOR GAMMA T AGONISTS | monomer | 100.0 | 1×Z7D; | |||
| CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) IN COMPLE… | monomer | 100.0 | 1×Z7G; | |||
| Crystal structure of RORgt with compound (4R)-6-[(2,5-dichloro-3-{[(2R,4R)-1-(cyclopentanecarbonyl)… | monomer | 99.59 | 1×VK4; 3×GOL; 1×SO4; | |||
| SUBSTITUTED BENZYLOXYTRICYCLIC COMPOUNDS AS RETINOIC ACID-RELATED ORPHAN RECEPTOR GAMMA T AGONISTS | monomer | 100.0 | 1×TKJ; | |||
| CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244- 487)-L6-SRC1(678-692)) IN COMPL… | monomer | 100.0 | 1×R7V; 1×GOL; | |||
| CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692) IN COMPLEX… | monomer | 100.0 | 1×YDY; | |||
| CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) IN COMPLE… | monomer | 100.0 | 1×Z7I; | |||
| SUBSTITUTED BENZYLOXYTRICYCLIC COMPOUNDS AS RETINOIC ACID-RELATED ORPHAN RECEPTOR GAMMA T AGONISTS | monomer | 100.0 | 1×Z7F; | |||
| Crystal structure of RORgt with 3-cyano-N-(3-{[(3S)-4-(cyclopentanecarbonyl)-3-methylpiperazin-1-yl… | monomer | 99.59 | 1×LKY; 6×EDO; | |||
| CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) IN COMPLE… | monomer | 100.0 | 1×Z7H; | |||
| CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(6T78-692) IN COMPLE… | monomer | 100.0 | 1×VK7; | |||
| CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS- RORGT(244-487)-L6-SRC1(678-692)) IN COMPL… | monomer | 100.0 | 1×O5B; 1×GOL; | |||
| CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692) IN COMPLEX… | monomer | 100.0 | 1×Z8G; | |||
| Crystal structure of RAR-related orphan receptor C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) in comple… | monomer | 100 | 1×O5A; | |||
| CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) IN COMPLE… | monomer | 100.0 | 1×Z8I; | |||
| Crystal structure of RORgammat with ligand C46D bound | monomer | 100 | 1×ENU; | |||
| X-ray structure of nuclear receptor ROR-gammat Ligand Binding Domain + SRC2 peptide | monomer | 100 | 1×NA; | |||
| X-ray co-structure of nuclear receptor ROR-GAMMAT + SRC2 peptide with a benzothiadiazole dioxide in… | monomer | 100 | 1×NA; 1×GOL; 1×ZBD; | |||
| X-ray co-structure of nuclear receptor ROR-gammat Ligand Binding Domain with an inverse agonist and… | monomer | 100 | 1×NA; 1×927; | |||
| Crystal structure of RORgammat with ligand C46D bound | monomer | 100 | 1×EKL; | |||
| X-ray co-structure of nuclear receptor ROR-gammat Ligand Binding Domain with an inverse agonist and… | monomer | 100 | 1×NA; 1×92A; | |||
| RORgamma (263-509) complexed with GSK2435341A and SRC2 | monomer | 100 | 1×43V; 2×SO4; | |||
| Crystal structure of the ROR(gamma)t ligand binding domain in complex with 4-(1-(2-chloro-6-(triflu… | monomer | 100 | 1×4F1; 1×MG; | |||
| X-ray co-structure of nuclear receptor ROR-gammat Ligand Binding Domain with an agonist and SRC2 pe… | monomer | 100 | 1×NA; 1×921; | |||
| Crystal structure of RORgammat with ligand C46D bound | monomer | 100 | 1×EO0; | |||
| RORgamma Ligand Binding Domain | monomer | 100 | 1×L77; | |||
| Complex structure of RORgama with betulinic acid | monomer | 100 | 1×06L; | |||
| Crystal structure of RORgammat with ligand C46D bound | monomer | 100 | 1×ENR; | |||
| RORgamma in complex with agonist BIO592 and Coactivator EBI96 | monomer | 100 | 1×6F1; 8×CL; | |||
| X-ray co-structure of nuclear receptor ROR-gammat Ligand Binding Domain with a inverse agonist and … | monomer | 100 | 1×NA; 1×9GS; | |||
| RORgamma LBD complexed with Panaxatriol and SRC2.2 | monomer | 100 | 1×HVL; | |||
| X-ray co-structure of nuclear receptor ROR-gammat Ligand Binding Domain with a inverse agonist and … | monomer | 100 | 1×9GV; | |||
| RORgamma Ligand Binding Domain | monomer | 100 | 1×L7J; | |||
| ROR(gamma)t ligand binding domain in complex with allosteric ligand FM216 | monomer | 99.59 | 1×UKB; | |||
| ROR(gamma)t ligand binding domain in complex with allosteric ligand FM26 | monomer | 99.59 | 1×L3E; | |||
| ROR(gamma)t ligand binding domain in complex with allosteric ligand FM257 | monomer | 99.59 | 1×UK8; | |||
| ROR(gamma)t ligand binding domain in complex with allosteric ligand FM217 | monomer | 99.59 | 1×U95; | |||
| Discovery of phenoxyindazoles and phenylthioindazoles as RORg inverse agonists | monomer | 100 | 1×79U; | |||
| ROR(gamma)t ligand binding domain in complex with 25-hydroxycholesterol and allosteric ligand FM26 | monomer | 99.58 | 1×HC3; 1×L3E; 1×GOL; | |||
| ROR(gamma)t ligand binding domain in complex with 20-alpha-hydroxycholesterol and allosteric ligand… | monomer | 99.58 | 2×GOL; 1×L3E; 1×HCD; | |||
| Identification of a Novel Allosteric Binding Site for RORgt Inhibitors | monomer | 99.58 | 1×4Y6; 2×SO4; 7×GOL; | |||
| ROR(gamma)t ligand binding domain in complex with desmosterol and allosteric ligand FM26 | monomer | 99.58 | 1×MHQ; 1×L3E; 1×GOL; | |||
| ROR(gamma)t ligand binding domain in complex with cholesterol and allosteric ligand MRL871 | monomer | 99.58 | 1×CLR; 1×4F1; 1×GOL; | |||
| ROR(gamma)t ligand binding domain in complex with 25-hydroxycholesterol and allosteric ligand Glenm… | monomer | 99.58 | 1×HC3; 1×MJE; 1×GOL; | |||
| ROR(gamma)t ligand binding domain in complex with desmosterol and allosteric ligand MRL871 | monomer | 99.58 | 1×MHQ; 1×4F1; 2×GOL; | |||
| ROR(gamma)t ligand binding domain in complex with cholesterol and allosteric ligand FM26 | monomer | 99.58 | 1×CLR; 1×L3E; 1×GOL; | |||
| ROR(gamma)t ligand binding domain in complex with 25-hydroxycholesterol and allosteric ligand MRL871 | monomer | 99.58 | 1×HC3; 1×4F1; 1×GOL; | |||
| Identification of a Novel Allosteric Binding Site for RORgt Inhibitors | monomer | 99.58 | 1×4Y7; 3×GOL; | |||
| Identification of a Novel Allosteric Binding Site for RORgt Inhibitors | monomer | 99.58 | 1×4Y5; 2×GOL; | |||
| Identification of a Novel Allosteric Binding Site for RORgt Inhibitors | monomer | 99.58 | 1×4F1; 4×GOL; 1×SO4; | |||
| ROR(gamma)t ligand binding domain in complex with allosteric ligand compound 13 (Glenmark) | monomer | 99.58 | 1×MJE; | |||
| Retinoic acid receptor-related orphan receptor (ROR) gamma in complex with allosteric compound 28 | monomer | 99.58 | 1×Q3Y; | |||
| ROR(gamma)t ligand binding domain in complex with allosteric ligand FM156 | monomer | 99.58 | 1×ULT; 1×GOL; | |||
| ROR(gamma)t ligand binding domain in complex with 20-alpha-hydroxycholesterol and allosteric ligand… | monomer | 99.58 | 2×GOL; 1×MJE; 1×HCD; | |||
| ROR(gamma)t ligand binding domain in complex with cholesterol and allosteric ligand Glenmark | monomer | 99.58 | 1×CLR; 1×MJE; 3×GOL; | |||
| ROR(gamma)t ligand binding domain in complex with 20-alpha-hydroxycholesterol and allosteric ligand… | monomer | 99.58 | 1×GOL; 1×HCD; 1×4F1; | |||
| ROR(gamma)t ligand binding domain in complex with desmosterol and allosteric ligand Glenmark | monomer | 99.58 | 1×MJE; 1×MHQ; 1×GOL; | |||
| The Crystal Structure of RORgT from Biortus. | monomer | 100 | ||||
| Crystal structure of RORc in complex with a benzyl sulfonamide inverse agonist | monomer | 100 | 1×3SX; 1×SO4; | |||
| Crystal structure of RORc in complex with a tertiary sulfonamide inverse agonist | monomer | 100 | 1×39K; 1×DMS; | |||
| Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for … | monomer | 99.57 | 1×444; | |||
| RORgamma Ligand Binding Domain | monomer | 100 | 1×L7P; | |||
| HUMAN RETENOID-RELATED ORPHAN RECEPTOR-GAMMA LIGAND- BINDING DOMAIN IN COMPLEX WITH INDOLE LIGAND C… | monomer | 100 | 1×F7M; | |||
| Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for … | monomer | 99.56 | 1×98E; | |||
| RORC2 LBD complexed with compound 34 | monomer | 99.13 | 1×F7J; | |||
| Ligand complex of RORgt LBD | monomer | 100 | 1×9A0; 5×EDO; 1×DMF; | |||
| Ligand complex of RORg LBD | monomer | 100.0 | 1×D9N; | |||
| RORCVAR2 (RORGT, 264-499) IN COMPLEX WITH COMPOUND 4 AT 2.2A: Identification of N-aryl imidazoles a… | monomer | 99.56 | 1×HKZ; | |||
| IDENTIFICATION OF BICYCLIC HEXAFLUOROISOPROPYL ALCOHOL SULFONAMIDES AS RORGT/RORC INVERSE AGONISTS | monomer | 100 | 1×XGH; 1×SO4; | |||
| Crystal structure of Retinoic acid receptor-related orphan receptor (ROR) gamma ligand binding doma… | monomer | 100 | 1×6Q6; | |||
| Structure of RORgt in complex with a novel inverse agonist 2 | monomer | 100 | 1×CFJ; | |||
| Optimization and biological evaluation of thiazole-bis-amide inverse agonists of RORgt | monomer | 100 | 1×RG7; | |||
| Crystal structure of Retinoic acid receptor-related orphan receptor (ROR) gamma ligand binding doma… | monomer | 100 | ||||
| Crystal structure of Retinoic acid receptor-related orphan receptor (ROR) gamma ligand binding doma… | monomer | 100 | 1×6QW; | |||
| RORCVAR2 (RORGT, 264-499) IN COMPLEX WITH COMPOUND 2 AT 2.3A: Identification of N-aryl imidazoles a… | monomer | 99.56 | 1×HKE; 2×CHD; | |||
| RORCVAR2 (RORGT, 264-499) IN COMPLEX WITH COMPOUND 1: Identification of N-aryl imidazoles as potent… | monomer | 99.56 | 1×HJW; | |||
| Crystal structure of Retinoic acid receptor-related orphan receptor (ROR) gamma ligand binding doma… | monomer | 100 | 1×6QP; | |||
| Synthesis and biological evaluation of new triazolo and imidazolopyridine RORgt inverse agonists | monomer | 99.56 | 2×Q6Y; | |||
| Structural states of RORgt: X-ray elucidation of molecular mechanisms and binding interactions for … | monomer | 99.56 | 1×99N; | |||
| RORCVAR2 (RORGT, 264-499) IN COMPLEX WITH COMPOUND 9 AT 2.3A: Identification of N-aryl imidazoles a… | monomer | 99.56 | 2×HL8; | |||
| Crystal structure of Retinoic acid receptor-related orphan receptor (ROR) gamma ligand binding doma… | monomer | 100 | 1×444; | |||
| Structure of RORgt bound to | monomer | 100 | 1×87J; | |||
| Identification and biological evaluation of thiazole-based inverse agonists of RORgt | monomer | 100 | 1×FJG; | |||
| Structure of RORgt bound to | monomer | 100 | 1×88J; | |||
| RORgamma in complex with inverse agonist 4j. | monomer | 100 | 1×4Q3; | |||
| Crystal structure of RAR-related orphan receptor C in complex with a phenyl (3-phenylpyrrolidin-3-y… | monomer | 100 | 1×L8A; | |||
| Structure of RORgt bound to | monomer | 100 | 1×8A4; | |||
| Crystal Structure Analysis of the ROR gamma(C455E) | monomer | 99.55 | 1×B6L; | |||
| Crystal structure of Retinoic acid receptor-related orphan receptor (ROR) gamma ligand binding doma… | monomer | 100 | 1×6Q5; | |||
| Crystal structure of human ROR gamma LBD in complex with a quinoline sulfonamide inverse agonist | monomer | 100 | 1×HBW; | |||
| CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C IN COMPLEX WITH A NOVEL INVERSE AGONIST | monomer | 100 | 1×V27; | |||
| Crystal structure of the ligand binding domain of RORC with T0901317 | monomer | 100 | 1×444; | |||
| Identification and biological evaluation of tertiary ALCOHOL-based inverse agonists of RORgt | monomer | 100 | 1×KHY; | |||
| Crystal structure of human ROR gamma LBD in complex with a (quinolinoxymethyl)benzamide inverse ago… | monomer | 100.0 | 1×LK8; | |||
| RORgamma in complex with inverse agonist BIO399. | monomer | 100 | 1×6EW; | |||
| RORgamma in complex with inverse agonist 16 | monomer | 100 | 1×4P1; | |||
| Structure of RORgt in complex with a novel inverse agonist 3 | monomer | 100 | 1×CF7; | |||
| RORy in complex with inverse agonist 3. | monomer | 100 | 1×5RT; | |||
| Structure of RORgt in complex with a novel inverse agonist. | monomer | 100 | 1×SO4; 1×MPD; 1×HQ7; | |||
| Crystal Structure of the Human ROR gamma Ligand Binding Domain With 3g | monomer | 100 | 1×4LQ; | |||
| RORgamma in complex with inverse agonist 48 | monomer | 100 | 1×4P3; | |||
| Structure of RORgt in complex with a novel inverse agonist TAK-828. | monomer | 100 | 1×MPD; 1×E3V; | |||
| Crystal structure of the orphan nuclear receptor ROR(gamma)t ligand-binding domain in complex with … | monomer | 100 | 1×DGX; | |||
| Structure of RORgt in complex with a novel inverse agonist 1 | monomer | 100 | 1×CFG; | |||
| Structure of RORgt in complex with a novel isoquinoline inverse agonist. | monomer | 100 | 1×MPD; 1×E3S; | |||
| CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C IN COMPLEX WITH A POTENT, SELECTIVE AND ORALLY B… | monomer | 100 | 1×VBG; 1×SO4; | |||
1 SWISS-MODEL model
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 3dzy.1.B | monomer | 0.50 | 1×ZN; | 31.30 | ||
1 SWISS-MODEL model built on isoform sequence
| Isoform | Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|---|
| Isoform 2 | 3dzu.1.B | monomer | 0.50 | 1×ZN; | 31.20 | ||